GlassScriptPhysician profile
Yue Zhang
NPI 1881906311
$105,366.90
in general payments reported to CMS, 2019-2025
29 companies · $31K in 2025
The $31K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $3,903 · 2021: $1,707 · 2022: $3,724 · 2023: $16K · 2024: $47K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Consulting Fee: $34K · Travel and Lodging: $17K · Honoraria: $5,610 · Food and Beverage: $2,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,877.00 |
| Consulting Fee | $33,802.50 |
| Travel and Lodging | $17,153.98 |
| Honoraria | $5,610.00 |
| Food and Beverage | $2,025.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40,702.30 | 2020-2025 | Keytruda |
| Exelixis INC. | $11,700.93 | 2019-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $9,988.60 | 2019-2025 | Imfinzi |
| Seagen INC. | $7,896.26 | 2023 | Adcetris |
| Eisai INC. | $7,856.84 | 2020-2024 | |
| Ipsen Biopharmaceuticals, INC | $5,532.14 | 2021-2024 | Onivyde |
| Gilead Sciences, INC. | $4,373.33 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,552.50 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,859.88 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $2,632.00 | 2025 | |
| Taiho Oncology, INC. | $1,750.00 | 2024 | |
| Daiichi Sankyo INC. | $1,509.99 | 2021-2024 | |
| G1 Therapeutics, INC. | $1,500.00 | 2022 | |
| Beigene USA, INC. | $1,375.00 | 2024 | Tevimbra |
| Astrazeneca Uk Limited | $1,044.00 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $173.62 | 2021-2022 | |
| Array Biopharma INC | $150.00 | 2025 | Mektovi, Lorbrena, Braftovi |
| Sirtex Medical INC | $145.46 | 2022 | |
| Stemline Therapeutics INC. | $131.44 | 2025 | Orserdu |
| Novartis Pharmaceuticals Corporation | $124.76 | 2019 | |
| Comsort, INC | $100.00 | 2019 | |
| Sobi, INC | $98.26 | 2023 | |
| Incyte Corporation | $91.46 | 2020 | |
| Janssen Biotech, INC. | $78.13 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yue Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.